Equities analysts expect Nu Skin Enterprises, Inc. (NYSE:NUS) to report sales of $669.57 million for the current quarter, Zacks reports. Two analysts have made estimates for Nu Skin Enterprises’ earnings, with estimates ranging from $666.16 million to $672.98 million. Nu Skin Enterprises posted sales of $531.33 million during the same quarter last year, which suggests a positive year-over-year growth rate of 26%. The firm is scheduled to issue its next quarterly earnings results after the market closes on Thursday, February 15th.
On average, analysts expect that Nu Skin Enterprises will report full-year sales of $669.57 million for the current fiscal year, with estimates ranging from $2.28 billion to $2.29 billion. For the next fiscal year, analysts forecast that the company will post sales of $2.36 billion per share, with estimates ranging from $2.34 billion to $2.37 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Nu Skin Enterprises.
NUS has been the topic of several research reports. ValuEngine raised Nu Skin Enterprises from a “hold” rating to a “buy” rating in a report on Sunday, December 31st. Citigroup reissued a “buy” rating and issued a $81.00 target price (up previously from $70.00) on shares of Nu Skin Enterprises in a report on Tuesday, January 23rd. Finally, Zacks Investment Research lowered Nu Skin Enterprises from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $65.38.
Large investors have recently modified their holdings of the company. Cerebellum GP LLC purchased a new stake in shares of Nu Skin Enterprises in the fourth quarter valued at $124,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Nu Skin Enterprises in the third quarter valued at $148,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Nu Skin Enterprises by 38.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,082 shares of the company’s stock valued at $210,000 after acquiring an additional 858 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Nu Skin Enterprises in the fourth quarter valued at $220,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Nu Skin Enterprises in the third quarter valued at $219,000. Institutional investors and hedge funds own 78.00% of the company’s stock.
Nu Skin Enterprises (NYSE NUS) opened at $67.60 on Friday. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $3,509.65, a price-to-earnings ratio of 24.76, a P/E/G ratio of 2.07 and a beta of 1.46. Nu Skin Enterprises has a twelve month low of $47.10 and a twelve month high of $74.45.
About Nu Skin Enterprises
Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.